Compare Barclays PLC (BCS) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barclays PLC vs Bristol-Myers Squibb Co — how do they compare? Barclays PLC trades at $28 (market cap $93.87B), while Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BCS | BMY | |
|---|---|---|
Market Cap | $93.87B | $129.94B |
Sector | Financials | Health |
52-Week High | $28.56 | $65.89 |
52-Week Low | $19.36 | $42.60 |
Dividend Yield | 2.19% | 3.96% |
Enterprise Value | — | $163.92B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
